Source: Annual Congress 2005 - Applied physiology in clinical practice



Rating:

Share or cite this content

Citations should be made in the following way:
S. Gregersen, A. Holm, P. Aukrust, J. Kongerud, S. S. Frøland, B. Johansen (Oslo, Norway). Tumor necrosis factor and pulmonary gas transfer in common variable immunodeficiency. Eur Respir J 2005; 26: Suppl. 49, 4343

Member's Comments

No comment yet.

Related content which might interest you: Tumor necrosis factor α in chronic pulmonary diseases of children Source: Eur Respir J 2002; 20: Suppl. 38, 193s Year: 2002 Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene Source: Eur Respir J 2002; 19: 912-918 Year: 2002 Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD Source: Eur Respir J 2007; 30: 810-812 Year: 2007 Tumor necrosis factor-alpha and CD4/CD8 ratio in patients with hypersensitivity pneumonitis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Source: Eur Respir J 2007; 29: 8-10 Year: 2007 Vascular endothelial growth factor and tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 353s Year: 2006 Tumor necrosis factor-α and interleukin-6 gene polymorphisms in pulmonary embolism Source: Eur Respir J 2005; 26: Suppl. 49, 520s Year: 2005 Tumour necrosis factor gene polymorphisms and childhood wheezing Source: Eur Respir J 2005; 26: 637-646 Year: 2005 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Low plasma stem cell factor combined with high transforming growth factor-a identifies high-risk patients in pulmonary arterial hypertension Source: ERJ Open Res, 4 (4) 00035-2018; 10.1183/23120541.00035-2018 Year: 2018 Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers Source: Eur Respir J 2007; 29: 34-41 Year: 2007 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 Role of tumor necrosis factor alpha in hepatopulmonary syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 562s Year: 2004 Tumour necrosis factor and signal transducer and activator of transcription 3 pathways; novel targets to treat severe influenza virus infection Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019 Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002 Cytokines in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 50S-59S Year: 2001 Pleural fibrosis induced by transforming growth factor (TGF)-β1 gene transfer Source: Eur Respir J 2005; 26: Suppl. 49, 100s Year: 2005 Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial Source: Eur Respir J 2014; 43: 295-298 Year: 2004